Distinct microglial and macrophage distribution patterns in the concentric and lamellar lesions in Baló's disease and neuromyelitis optica spectrum disorders.
Baló's disease
distal oligodendrogliopathy
macrophage
microglia
neuromyelitis optica spectrum disorders
Journal
Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
14
04
2020
revised:
23
08
2020
accepted:
23
09
2020
pubmed:
10
9
2020
medline:
7
10
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
TMEM119 and purinergic receptor P2Y12 (P2RY12), which are not expressed by recruited peripheral blood macrophages, are proposed to discriminate microglia from macrophages. Therefore, we investigated the distribution patterns of microglia and macrophages in 10 concentric lesions from four autopsied Baló's disease cases and one neuromyelitis optica spectrum disorder (NMOSD) case, using quantitative immunohistochemistry for the markers TMEM119, P2RY12, CD68, CD163 and GLUT5. Three cases with Baló's disease had distal oligodendrogliopathy (DO) showing preferential loss of myelin-associated glycoprotein and early active demyelination in the outermost demyelinating layer (termed DMY-MO). In DMY-MO with DO, TMEM119-positive activated microglia expressing upregulated GLUT5 but markedly downregulated P2RY12 were significantly increased. These activated microglia expressed inducible nitric oxide synthase. Oligodendrocytes and their precursors showed apoptotic-like nuclear condensation in DMY-MO. TMEM119-negative and CD68/CD163-positive macrophages were distributed throughout the lesion center of DMY-MO with DO and these cells demonstrated foamy morphology only in the inner portion but not in the outer portion. In concentric demyelinating lesions from another Baló's case and lamellar demyelinating lesions in an NMOSD case, which had late active demyelination without DO, the densities of TMEM119-, GLUT5- and P2RY12-positive microglia with ramified morphology were significantly increased in myelinated layers but not in demyelinating layers. In particular, in the NMOSD case, TMEM119-positive microglia were confined to the outer portion of the myelinated layers. CD68-positive macrophages with foamy morphology also expressing CD163 accumulated in myelinated as well as in demyelinated layers. These findings suggest that activated microglia expressing TMEM119 and GLUT5, but not P2RY12, are associated with apoptosis of oligodendrocytes in the leading edge of Baló's concentric lesions with DO, whereas TMEM119-, GLUT5- and P2RY12-positive microglia with ramified morphology are associated with myelin preservation in concentric lesions without DO in Baló's disease and NMOSD. These two types of microglia appear to play distinct roles in the formation of concentric lesions.
Identifiants
pubmed: 32902014
doi: 10.1111/bpa.12898
pmc: PMC8018076
doi:
Substances chimiques
Glucose Transporter Type 5
0
Membrane Proteins
0
P2RY12 protein, human
0
Receptors, Purinergic P2Y12
0
Tmem119 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1144-1157Subventions
Organisme : the Ministry of Health, Labour and Welfare, Japan
ID : H26-Nanchitou(Nan)-Ippan-074
Organisme : JSPS KAKENHI Grants-in-Aid for Scientific Research (C)
ID : 16K09694
Organisme : the Japan Agency for Medical Research and Development (AMED)
ID : 18ek0109308h0001
Organisme : JSPS KAKENHI Grants-in-Aid for Scientific Research (A)
ID : 19H01045
Organisme : a "Glial assembly" Grant-in-Aid for Scientific Research on Innovative Areas
ID : 25117001
Organisme : a "Glial assembly" Grant-in-Aid for Scientific Research on Innovative Areas
ID : 25117012
Informations de copyright
© 2020 International Society of Neuropathology.
Références
Mult Scler. 2008 Apr;14(3):418-24
pubmed: 18208888
Mult Scler. 2018 Aug;24(9):1258-1261
pubmed: 29676196
J Neurol. 2010 Sep;257(9):1566-7
pubmed: 20352246
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
Acta Neuropathol. 2003 Feb;105(2):157-62
pubmed: 12536226
Neuroscience. 2010 Mar 17;166(2):464-75
pubmed: 20035837
Sci Rep. 2016 Apr 14;6:24240
pubmed: 27074918
Glia. 2017 Feb;65(2):375-387
pubmed: 27862351
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46
pubmed: 26884166
Diabetes Care. 2007 Apr;30(4):925-31
pubmed: 17251278
J Neurochem. 2016 Jan;136 Suppl 1:10-7
pubmed: 25693054
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E141-5
pubmed: 20009031
Ann Neurol. 1995 Apr;37(4):424-35
pubmed: 7536402
Bone. 2012 Jul;51(1):158-67
pubmed: 22579779
Lancet Neurol. 2014 Jul;13(7):740-6
pubmed: 24943346
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Glia. 1997 Nov;21(3):327-31
pubmed: 9383041
Nat Neurosci. 2013 Sep;16(9):1211-1218
pubmed: 23872599
Immunology. 2014 Mar;141(3):302-13
pubmed: 23981039
Blood Cells Mol Dis. 2004 Jan-Feb;32(1):182-90
pubmed: 14757434
Acta Neuropathol. 2010 Nov;120(5):651-60
pubmed: 20680636
Intern Med. 2013;52(13):1517-21
pubmed: 23812202
Nat Neurosci. 2014 Jan;17(1):131-43
pubmed: 24316888
Neuropathology. 2016 Feb;36(1):39-49
pubmed: 26250788
J Neurol Sci. 2009 Apr 15;279(1-2):114-7
pubmed: 19181346
Arch Neurol. 2009 Feb;66(2):274-5
pubmed: 19204169
Am J Physiol. 1998 Mar;274(3):E516-26
pubmed: 9530136
Cancer Cell. 2016 Nov 14;30(5):779-791
pubmed: 27746145
Brain. 2017 Jul 1;140(7):1900-1913
pubmed: 28541408
Neurol Sci. 2004 Nov;25 Suppl 4:S361-3
pubmed: 15727234
Acta Neuropathol. 2012 Jun;123(6):887-900
pubmed: 22438105
Ann Neurol. 1995 Nov;38(5):788-96
pubmed: 7486871
Mol Cell Neurosci. 2006 Jan;31(1):149-60
pubmed: 16297637
J Biol Chem. 1992 Jul 25;267(21):14523-6
pubmed: 1634504
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12041-5
pubmed: 8618840
Brain. 2005 May;128(Pt 5):979-87
pubmed: 15774507
Mult Scler. 2011 Jul;17(7):771-9
pubmed: 21459811